Project Details
| Short title | MK-2870-010 |
|---|---|
| Status | Active |
| Effective start/end date | 1/08/24 → 20/05/29 |
CTU: An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2-Unresectable Locally Advanced or Metastatic Breast Cancer.
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
Project: Research